Ruben Niesvizky
Experienced in Primary Immunodeficiency (PID)

Dr. Ruben Niesvizky

Hematology Oncology | Oncology | Hematology
Weill Medical College Of Cornell
520 E 70th St, 
New York, NY 
Offers Telehealth
Experienced in Primary Immunodeficiency (PID)
Weill Medical College Of Cornell
520 E 70th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ruben Niesvizky is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Niesvizky is rated as an Experienced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 113 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
520 E 70th St, New York, NY 10021
Other Locations
WEILL MEDICAL COLLEGE OF CORNELL
425 E 61st St, Fl 4, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: EZM0414
Study Phase: Phase 1
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: SEA-BCMA, Dexamethasone, Pomalidomide
Study Phase: Phase 1
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drugs: ACY-241, Pomalidomide, Dexamethasone
Study Phase: Phase 1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drug: STRO-001
Study Phase: Phase 1
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2023
Intervention Type: Drug
Study Drugs: Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
Study Phase: Phase 2
A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Drug
Study Drugs: TAK-079, Pomalidomide, Dexamethasone
Study Phase: Phase 1/Phase 2
A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma or Lymphoma
A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma or Lymphoma
Enrollment Status: Completed
Publish Date: December 27, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 26, 2019
Intervention Type: Drug
Study Phase: Phase 3
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: August 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Open-Label Study of the Safety and Efficacy of PD 0332991 (Palbociclib) in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Open-Label Study of the Safety and Efficacy of PD 0332991 (Palbociclib) in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: August 22, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

113 Total Publications

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Journal: Nature genetics
Published: June 09, 2025
Similar Doctors
Distinguished in Primary Immunodeficiency (PID)
Dr. Adriana C. Rossi
Oncology | Hematology | Hematology Oncology
Distinguished in Primary Immunodeficiency (PID)
Dr. Adriana C. Rossi
Oncology | Hematology | Hematology Oncology

Icahn School Of Medicine At Mount Sinai

10 E 102nd St, Tisch Dept Of Mount Sinai, 
New York, NY 
 (1.8 miles away)
212-844-8288
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adriana Rossi is an Oncologist and a Hematologist in New York, New York. Dr. Rossi is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Primary Immunodeficiency (PID)
Dr. Allyson Flower
Hematology | Oncology
Advanced in Primary Immunodeficiency (PID)
Dr. Allyson Flower
Hematology | Oncology

Bradhurst Avenue Specialty Office

19 Bradhurst Avenue, 
Hawthorne, NY 
 (23.7 miles away)
914-614-4270
Languages Spoken:
English
See accepted insurances

Allyson Flower is a Hematologist and an Oncologist in Hawthorne, New York. Dr. Flower is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Myelodysplastic Syndrome (MDS), Primary Immunodeficiency (PID), Sickle Cell Disease, Bone Marrow Transplant, and Bone Marrow Aspiration.

Mitchell Cairo
Advanced in Primary Immunodeficiency (PID)
Dr. Mitchell Cairo
Hematology | Oncology
Advanced in Primary Immunodeficiency (PID)
Dr. Mitchell Cairo
Hematology | Oncology

Bradhurst Avenue Specialty Office

19 Bradhurst Avenue, 
Hawthorne, NY 
 (23.7 miles away)
914-614-4270
Languages Spoken:
English
See accepted insurances

Mitchell Cairo is a Hematologist and an Oncologist in Hawthorne, New York. Dr. Cairo is rated as an Elite provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Burkitt Lymphoma, B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Niesvizky's expertise for a condition
ConditionClose
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile